Business Context and Reporting Period
Company: Actinium Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 5, 2020
Principal Executive Offices: 275 Madison Avenue, 7th Floor, New York, NY 10016
This filing reports a corporate governance amendment adopted by the Board of Directors on May 5, 2020. The company is incorporated in Delaware and its common stock trades on the NYSE American under the symbol ATNM.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report regarding a bylaw amendment and does not contain financial statements or performance metrics.
Material Changes
Bylaw Amendment (Item 5.03): On May 5, 2020, the Board amended the Company's bylaws to adopt a new Article XI, titled "Exclusive Forum."
- Provision: Designates the federal district courts of the United States as the exclusive jurisdiction for any litigation arising under the Securities Act of 1933, as amended.
- Reference: The full text of the Amended Bylaws is included as Exhibit 3.01 to this report.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, or specific risk factors beyond the legal implications of the new exclusive forum provision. No unusual items or contingencies were disclosed in this report.
Key Facts for Investor Verification
- Verify the full text of the Amended Bylaws in Exhibit 3.01 to understand the scope of the "Exclusive Forum" provision.
- Confirm the impact of the exclusive federal jurisdiction on potential shareholder litigation strategies.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial performance.